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Abstract
Background: We investigated the change of prognosis in resected gastric cancer (RGC) patients
and the role of radical surgery and adjuvant chemotherapy.
Methods: We retrospectively analyze the outcome of 426 consecutive patients from 1975 to
2002, divided into 2 time-periods (TP) cohort: Before 1990 (TP1, n = 207) and 1990 or after (TP2;
n= 219). Partial gastrectomy and D1-lymphadenetomy was predominant in TP1 and total
gastrectomy with D2-lymphadenectomy it was in TP2. Adjuvant chemotherapy consisted of
mitomycin C (MMC), 10–20 mg/m2 iv 4 courses or MMC plus Tegafur 500 mg/m2 for 6 months.
Results:  Positive nodes were similar in TP2/TP1 patients with 56%/59% respectively. Total
gastrectomy was done in 56%/45% of TP2/TP1 respectively. Two-drug adjuvant chemotherapy was
administered in 65%/18% of TP2/TP1 respectively. Survival at 5 years was 66% for TP2 versus 42%
for TP1 patients (p < 0.0001). Survival by stages II, IIIA y IIIB for TP2 versus TP1 patients was 70
vs. 51% (p = 0.0132); 57 vs. 22% (p = 0.0008) y 30 vs. 15% (p = 0.2315) respectively. Multivariate
analysis showed that age, stage of disease and period of treatment were independent variables.
Conclusion: The global prognosis and that of some stages have improved in recent years with case
RGC patients treated with surgery and adjuvant chemotherapy.
Background
For many authors, gastric carcinoma remains one of the
leading causes of cancer death worldwide, second only to
lung carcinoma [1,2]. Five-year relative survival of
patients from European countries ranges from 10 to 30%
[3,4], similar to that reported in USA (15 to 28%) [5].
Local and regional gastric carcinoma showed a 5-year rel-
ative survival of 55–59% and 20–22% respectively [6]. In
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this latter subgroup of patients the surgical treatment of
choice consisted of gastrectomy combined with regional
lymph node dissection. The relevance of radical surgery,
extending lymph node dissection as wide as possible has
been highlighted. The experience of an expert surgeon has
been shown to improve clinical outcome in some tumors
[7]. In the statistical outcome of two European trials, one
from the United Kingdom and the other, The Nether-
lands, comparing D1 versus D2 lymphadenectomy a sur-
vival rate of approximately 20% for D1 group was
assumed [8,9]. This 20% overall survival was based on
historic data from both those countries. Nevertheless, the
overall 5-year survival for D1 group jumped to 34% and
45% respectively, without any dramatic change in T clas-
sification distribution, suggesting that the results from
expert surgeons may improve final cure rates [10,5].
In spite of surgical treatment, thousands of loco-regional
gastric cancer patients relapse and die worldwide each
year. Taking into account the poor survival of gastric car-
cinoma after treatment only with surgery, several adjuvant
strategies have been developed in recent years to reduce
relapse rates and to improve long-term survival. Survival
rates of up to 40% in selected patients receiving postoper-
ative adjuvant chemoradiation has been obtained after
curative resection (R0) in contrast to 30% survival if
patients were treated with surgery alone [11]. Japanese
authors have proposed that improvement in survival can
be also achieved with surgery plus adjuvant chemother-
apy based on mitomycin and fluorouracil derivates [12],
thus avoiding toxic effects through radiotherapy. Like-
wise, our group reported a 60% 5-year survival among
patients with loco-regional gastric carcinoma treated with
gastrectomy followed by 6 months of chemotherapy
based on mitomycin-C and tegafur (a 5-fluoruracil pro-
drug) without radiotherapy [13,14].
Our prospectively maintained database contains data on
patients with early and locally advanced gastric carcinoma
treated with surgery since 1975. After 1990 the principal
surgical option was D2 dissection plus gastrectomy. Ini-
tially, patients who achieved disease-free status after sur-
gery were offered the option of adjuvant chemotherapy
within a clinical trial or follow-up with no further therapy.
After 1990, we offered adjuvant chemotherapy to all
patients. In order to evaluate the improvement in the
prognosis among operated gastric cancer patients, we
have retrospectively compared the long-term therapeutic
results of patients diagnosed and treated at our institution
before and after 1990.
In this study, we analyzed the outcome and survival of
resected non-metastatic gastric cancer patients over this
time period, comparing the periods before and after 1990
when Japanese-style surgery followed by adjuvant chemo-
therapy were included as the preferable treatment option
for the majority of patients.
Patients and methods
This retrospective study includes 426 consecutive non-
metastatic patients who underwent primary surgery for
gastric adenocarcinoma with curative R0 intent (stages Ia
to IV M0).
Since 1975, patients with early or locally advanced gastric
adenocarcinoma have been operated with subtotal or
total gastrectomy according to the location and the size of
the primary tumor. The range of lymph node resection
was performed following the classification and rules of
the Japanese Research Society for the Study of Gastric Can-
cer [15]. D1 resections were performed until 1990 when,
after a 6-months training program in Japan, surgeons
standardized the use of the more extended D2 dissection
at our institution. Resections of spleen and tail of pancreas
were performed in proximal gastric tumors to achieve ade-
quate removal of D2 lymph node stations 10 and 11.
Each patient was staged according to the tumor-node-
metastasis system valid at the time of surgery. Recently,
the database has been updated and patients diagnosed
before 1997 were re-staged according to the latest guide-
lines of the AJCC published in 1997 [16].
Adjuvant chemotherapy
From 1975 to 1990, patients after complete resection of
gastric cancer were offered adjuvant chemotherapy treat-
ment within clinical trials or they were followed up with-
out treatment. Since 1990, adjuvant chemotherapy has
been offered to all patients, both within and outside the
framework of clinical trials. Two different chemotherapy
schedules were used: Mitomycin-C (MMC) 10–20 mg/m2
i.v. bolus once every 6 weeks, or MMC plus Tegafur (TG)
500 mg/m2 p.o. daily. Both regimens were administered
during 6 months after surgery. After 1995, MMC-TG was
routinely to all patients out of clinical trials. After adju-
vant treatment, all patients were followed up with clinical
checking, biochemical blood test, including tumor mak-
ers (CEA and CA 19.9), chest X-ray film, and liver ultra-
sonography every 3 to 6 months for five years and yearly
thereafter. Other explorations such as CT-scan or endos-
copy were performed if clinical or complementary test
alterations appeared.
Statistical analysis
Follow-up and survival data were recorded according to
the rules set down by Peto et al [17]. The database was last
updated on 30 November 2004. In this study, data were
retrospective analyzed. For statistical analysis the SPSS
program (version 11.0, SPSS Inc, Chicago) was used.
Comparison between groups based on patient's character-World Journal of Surgical Oncology 2006, 4:53 http://www.wjso.com/content/4/1/53
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istics was performed using the χ2test for discrete data and
t-test for continuous data, both two-tailed. Patients were
divided firstly in two groups, depending on the time
period (TP) in which they received treatment i.e. TP1 =
1975–1989, and TP2 = 1990–2002. Secondly, global sur-
vival of all patients was divided in five-year period). Sur-
vival probabilities were estimated by the Kaplan-Meier
product-limit method [18] and the log-rank test was used
to evaluate the difference between survival curves [19]. A
p-value of 0.05 was considered to be the limit of signifi-
cance for all analysis.
Cox's proportional hazard model with covariates for main
prognostic factors like gender, positive lymph nodes,
adjuvant chemotherapy and period of treatment was
applied.
Results
Patient characteristics are outlined in Table 1. In the TP1,
207 patients were included in the study as they were diag-
nosed and treated for primary gastric cancer, while in TP2,
the patients included with the same criteria were 219.
There were no significant differences in gender distribu-
tion, with a male/female ratio of 2/1. Patients TP2 were
older than the TP1 (>61 years: 46% vs. 68%; p = 0,001).
Distribution of tumor location was well balanced. The
proportion of T1/T2 tumors in TP2 patients was higher
compared with those TP1 patients (35% versus 21%, p <
0,001). There were no differences between the two groups
in the proportion of node positive/negative staging,
(56.1%/43.8% in TP2 patients and 58.9%/41.1% in TP1
patients). Because the staging rules, node positive N3
tumors were observed in 9 out of 219 (4%) (TP2 patients
versus none in TP1 patients). In spite of these differences,
a similar distribution of stages was seen in both groups,
stage I plus II/stage III plus IV in TP2 patients (50.2%/
49.8) compared with those TP1 patients (47.4%/
52.6%)(p = 0,562).
Table 1: Patient's demographics and tumors characteristics
Year of diagnostic
Before 1990 1990 and after
(n = 207) (n = 219)
Total % n % n ρ 
Gender = .919
Male 276 64.9 135 64.4 141
Female 150 35.1 72 35.6 78
Age. years < .001
< 61 182 54.1 112 31.7 70
> 61 244 45.9 95 68.3 149
Tumor location* = .097
Cardia 32 6.3 10 11.6 22
Body 130 37.3 61 36.5 69
Antrum 187 56.3 89 51.9 98
Local invasion** < .001
T1 44 2.9 6 17.4 38
T2 76 17.9 37 17.8 39
T3 294 78.7 163 59.7 131
T4 12 0.5 1 5.1 11
Lymph node involvement*** = .624
N0 181 41.1 85 43.8 96
N1 141 36.2 75 30.1 66
N2 95 22.7 47 21.9 48
N3 9 0.0 0 4.1 9
Stage**** = .562
IA 34 0.5 1 15.0 33
IB 58 15.5 32 11.9 26
II 116 31.4 65 23.3 51
IIIA 118 30.9 64 24.7 54
IIIB 83 21.3 44 17.8 39
IV 17 0.5 1 7.3 16
* ; Not specified in 77 patients (47 in PT1 and 30 in PT2)World Journal of Surgical Oncology 2006, 4:53 http://www.wjso.com/content/4/1/53
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Surgery
Treatment characteristics are shown in Table 2. All
patients underwent subtotal or total gastrectomy: 44%/
56% for TP2 patients, and 55%/45% for TP1 patients
respectively. Twenty-nine splenectomies were performed,
four of them with subtotal gastrectomy and twenty-five
with total gastrectomy. More extended lymph node dis-
sections were performed among the TP2 patients com-
pared with those PT1 patients (D2 65% vs. 10%,
respectively).
Perioperative mortality in TP2 patients was 4% (9 out of
219), mainly by sepsis or pulmonary thromboembolism,
and 1% (2 out of 207) (p = 0.091) in TP1 patients.
Forty-five percent of the patients received no adjuvant
treatment after surgery, followed by clinical checking until
progression or death. No difference was observed in the
rate of patients that received no adjuvant chemotherapy
between both TP2/TP1 periods (42.7% versus 47.3%; p =
.436). Among those patients who received adjuvant
chemotherapy, the MMC-TG combination was the most
frequently prescribed regimen in TP2 patients (65%)
compared with MMC alone, the most commonly used
treatment in TP1 patients (82%).
Survival analysis
Median follow-up for all patients was 216 months. At the
time of analysis, the 219 TP2 patients had a median fol-
low up of 96 months, whereas the 207 TP1 patients had
been followed-up for a median of 260 months. Median
survival was 120+ months (median not reached) and
32.31 months for each period, respectively. 5-year overall
survival was 66% for TP2 patients versus 42% for TP1
patients (p < 0.0001). Figure 1 shows a Kaplan-Meier sur-
vival curves with plateau  beginning in 5th year in both
groups, and maintains this line for more than 10 years.
Staging
When subgroups analysis was done according to the stag-
ing, the significant improvement in survival seems to be
restricted to stages II and IIIA, with an insignificant
improvement at stage IIIB (see table 3). Five-year overall
survival at stages II, IIIA and IIIB for each TP2/TP1 period
was 70% vs. 51% (p = 0.0132), 57 vs. 23% (p = 0.0008)
and 30 vs. 15% (p = 0.2315), respectively (Figure 2). Both
node negative and positive patients show better survival
in TP2 patients compared with those treated before 1990
(5-year overall survival: 73% versus 62%, p = 0.0328 and
53 versus 23%, p < 0.0001) (Figure 3). An improvement
in survival has been observed in D2 lymphadenectomy
patients comparing TP2 with TP1 (5-year overall survival:
66% versus 42%, p = 0.0076) as patients treated with
adjuvant chemotherapy as patients non treated with adju-
vant chemotherapy.
Survival and adjuvant chemotherapy
When comparing the outcome of patients treated with
adjuvant chemotherapy using MMC only with those
patients treated with adjuvant MMC-TG during period
TP2, a better global survival was observed in patients
treated with the two-drug regimen. Global survival at 5
years for those treated with adjuvant MMC was 58% for
TP2 patients, and 47% for those TP1 patients but these
differences were not statistically significant (p = 0.2346.)
Nevertheless, for those TP2 patients treated with adjuvant
Table 2: Surgical Treatment and Adjuvant Chemotherapy Details
Year of diagnostic
Before 1990 1990 and after
Total % n % n ρ 
Gastrectomy = .055
Subtotal 168 55.3 83 44.3 85
Total 175 44.7 68 55.7 107
Splenectomy* 29 3.4 5 12.5 24
Lymphadenectomy** < .001
D1 249 89.3 184 34.6 65
D2 145 10.7 22 65.4 123
Adjuvant Chemotherapy = .436
No 192 47.3 98 42.7 94
Yes 235 52.7 109 57.3 126
Chemotherapy schedule < .001
MMC 133 81.7 89 34.9 44
MMC-TG 102 18.3 20 65.1 82
*; Not specified in 54 patients (47 in PT1 and 30 in PT2)
** Not specified in 32 patients (31 in PT1 and 1 in PT2)World Journal of Surgical Oncology 2006, 4:53 http://www.wjso.com/content/4/1/53
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MMC-TG, survival at 5 years was 87% while for TP1
patients the rate was 54% (p = 0.0113). MMC-TG was the
adjuvant chemotherapy in 44% of the patients after 1995
versus 20 % of the patients between 1990 and 1994.
Timing of treatment
When we look at the date when patients were diagnosed
and treated, if we divided in five-year period, we can see
that there is an improvement in survival in patients
treated more recently. The best results have been mainly
observed in patients treated after 1995 compared with
patients treated earlier with a rate of long term survivors
of 73% and 41% respectively (p < 0.0001).
The 87 patients treated between 1995 and 1999 have an
average follow-up of 90 months. Survival at 5 years is
67%. The 55 patients treated since 2000 have a follow-up
of 48 months and of these, 9 have died of the disease
(16%) and 4 more are alive but have been relapsed (7%)
(Figure 4).
The Cox multivariate analysis applied using the signifi-
cant variables in the univariate analysis showed that stage
(p = 0.002) and period (TP2 over TP1) (p < 0.001) of
treatment continue to be statistically significant as inde-
pendent variables. When we analyzed the period of treat-
ment before and after 1995 (instead of 1990) the stage (p
= 0.003) and period of treatment (p < 0.001) were also
independent variables.
Discussion
Gastric cancer can be a fatal disease even in its earliest
stages. There is a survival rate of approximately 40% at 5
years in patients with loco-regional disease. These patients
would be candidates for procedures such as gastrectomies
and lymphadenectomies. Nevertheless, as mentioned
before, an improvement in cure rates has been observed in
recent years. In some cases this improvement is produced
through surgery plus chemotherapy or radiotherapy but
in other cases, through expert surgery only. Patients with
affected lymph nodes in the postoperative pathological
staging have the worst prognosis. In our series, survival at
5 years in patients with positive nodes rose from 23% to
53% on the basis of whether they were treated before or
after 1990. These results are superior to those published
by Sasako et al [20], which were 30%–40%. This data sug-
gests that since 1990, there has been improved postoper-
ative staging and in contrast, prior to 1990, there may
have been patients who were down-staged.
When we compare patients treated after 1990, survival
rate at 5 years according with the stages, we can seen that
our results are similar to those published by Japanese
groups and both are better that those published by other
Western authors (Table 4).
Our results indicate an improvement in global survival in
patients treated after 1990 when D2 dissection and adju-
vant chemotherapy was the treatment applied in the
majority of patients. However, this improvement in sur-
vival is clearer still from 1995 onwards. The reasons for
this improvement cannot be explained simply by earlier
diagnosis in patients with earlier stage as it occurs in dif-
ferent stages of the disease. Only stage IIIB does not show
a significant statistical improvement in the survival curve,
probably because of the low number of patients of our
series in this situation. Better post-operative care was not
the explanation for this improvement, as perioperative
mortality was higher in patients treated after 1990 than
before, probably due to the greater number of D2 lym-
phadenectomy carried out. This procedure shows mortal-
ity rates higher than those of D0 and D1 dissections in the
majority of studies [21]. In addition, the majority of sur-
gical procedures were carried out by the same team of 4
surgeons who have acquired wider experience through the
years. There are evidences to show that the surgeon's
learning curve can improve the final results of treatment
[22] and partially explain the survival improvement after
1995.
Adjuvant chemotherapy with 2 drugs has shown itself to
be superior to that with MMC only [23]. Also, D2 surgery
along with chemotherapy with 2 drugs has demonstrated
long-term survival rates of up to 75%. All of this data sug-
gested that improved outcomes could be the result of bet-
Kaplan-Meier survival curves of all 426 gastric cancer patients Figure 1
Kaplan-Meier survival curves of all 426 gastric cancer 
patients. Patients treated in1990 and after had a significantly 
better long-term survival than those treated before that year 
(median survival of >120 m versus 28 m; p < 0.0001).
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ter surgery carried out by more experienced surgeons
together with adjuvant chemotherapy based on MMC
plus Tegafur.
Several factors could produce a time-related bias in the
studies focused on temporary improvements in survival of
diseases. These include changes in radiological facilities
for detection and diagnosis of metastases, changes in diag-
nostic criteria and evolution of clinical characteristics,
allowing a more accurate staging of the patients. Never-
theless, in our study, the radiological facilities used to
detect metastases of primary gastric cancer were similar
after 1990 and include liver ultrasound, chest X-rays, and
abdominal CT scan for confirmation.
One can argue that the improvement is related to poor
results in the first cohort. Nevertheless, the survival rates
observed during this time period (1975 to 1989) are not
different from those reported in other hospital-based
cohort studies [24]. Our study was not designed to iden-
tify what intervention led to survival improvements. Nev-
ertheless, several hypotheses could be put forward to
explain the improvements in survival observed in our
study. The first hypothesis is that advances in surgical
resection have led to improvements in survival. The study
by Bonenkamp et al [9] was unable to establish significant
differences between D1 and D2 resection. However, one
explanation would be that the D1 control group had
longer than expected survival due to the action of an expe-
rienced surgeon. If macroscopically visible lymph nodes
were found in the mesenteric region during a surgical
intervention, the original objective of which was a D1
resection, we must suppose that the resection proceeded
with a wider intervention to include those nodes and
therefore became a D2-like dissection.
As in other retrospective analysis [25], our study did not
assess which one of these surgical options has changed the
outcome of patients. Nevertheless, the predominant use
of adjuvant chemotherapy after D2 dissection showed the
best results. Post-surgical radiation therapy was not
included in the adjuvant treatment of these patients.
Table 3: Comparison of median survival and 5-year survival rates between subgroups of patients according to the period of treatment
Year of diagnostic
Before 1990 (n = 207) 1990 and after (n = 219)
n x OS (m) 5-y OS (%) n x OS (m) 5-y OS (%) ρ 
Gender
Male 135 26 32 141 120+ 58 < .0001
Female 72 113 53 78 120+ 69 = .0434
Age, years
< 61 112 34 42 69 120+ 57 = .0504
> 61 95 31 37 149 120+ 64 < .0001
Tumor location
Cardia 10 36 26 22 120+ 90 = .0021
Body 59 33 38 69 120+ 62 = .0022
Antrum 89 38 44 98 120+ 59 = .0253
Lymph node involvement
N0 85 216+ 62 96 120+ 73 = .0328
N+ 122 22 23 123 120+ 52 < .0001
Stage
I 33 204+ 81 59 120+ 81 = .6689
II 65 78 51 51 120+ 70 = .0132
IIIA 64 23 23 54 120+ 57 = .0008
IIIB 44 19 15 39 23 30 = .2315
Lymphadenectomy
D1 1 8 4 3 13 9 6 5 2 62 6 =  . 6 7 1 8
D2 22 52 42 123 120 66 = .0076
Adjuvant Chemotherapy
No 98 22 30 94 60 45 = .006
Yes 109 58 48 126 120+ 73 = .0003
Chemotherapy
MMC 89 48 47 44 120+ 58 = .2346
MMC-TG 20 80 54 82 120+ 87 = .0113World Journal of Surgical Oncology 2006, 4:53 http://www.wjso.com/content/4/1/53
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Kaplan-Meier survival curves of patients at stages I, II, IIIA and IIIB Figure 2
Kaplan-Meier survival curves of patients at stages I, II, IIIA and IIIB. Patients with stages II and IIIA treated in 1990 and after had 
a significantly better long-term survival than those treated before (median survival of >120 m versus 78 m; p = 0.0132 and >120 
m versus 23 m; p = 0.0008, respectively)
Kaplan-Meier survival curves of patients according to nodal involvement Figure 3
Kaplan-Meier survival curves of patients according to nodal involvement. Significantly better survival was observed among 
patients treated after 1990, independently of nodal involvement (5-y overall survival of 52% versus 23%; p = 0.0001 and 73% 
versus 62%; p = 0.0328, respectively)World Journal of Surgical Oncology 2006, 4:53 http://www.wjso.com/content/4/1/53
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Recent cure rates should be reconsidered as a point of ref-
erence for studies that are currently working with resecta-
ble gastric cancer [26]. On the other hand, our data
suggest that timing is an important prognostic factor
when treating patients with gastric cancer, probably
through improving the application of multidisciplinary
treatment. On the light of this retrospective analysis we
may suggest that Japanese-style gastrectomy with D2 lym-
phadenectomy carried out by expert surgeons, followed
by adjuvant chemotherapy with MMC-TG can be a good
option for treating Western patients with locally advanced
gastric cancer.
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